

# Gregory R Bluemling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1982772/publications.pdf>

Version: 2024-02-01

8  
papers

1,898  
citations

1307594

7  
h-index

1588992

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

2817  
citing authors

#	ARTICLE	IF	CITATIONS
1	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	886
2	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. <i>Nature</i> , 2021, 591, 451-457.	27.8	320
3	Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	253
4	Small-Molecule Antiviral 2'-5'-Dihydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. <i>Journal of Virology</i> , 2019, 93, .	3.4	252
5	The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. <i>Antiviral Research</i> , 2019, 171, 104597.	4.1	81
6	4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. <i>Science</i> , 2022, 375, 161-167.	12.6	58
7	Analysis of the Potential for 2'-5'-Dihydroxycytidine To Inhibit Mitochondrial Replication and Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	25
8	4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. <i>Science</i> , 2021, , eabj5508.	12.6	2